Navigation Links
RVX-208 Data Demonstrates Increase in Functional HDL Particles
Date:11/10/2008


Prebeta-HDL generation and improved HDL functionality are distinguishing

factors

TSX Exchange Symbol: RVX

NEW ORLEANS, LA, Nov. 10 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today key scientific data was presented in an oral presentation highlighting the novel features of RVX-208 at the American Heart Association Scientific Meeting. The presentation titled "Compound RVX-208 Modulates HDL-C Levels and Function in Non-human Primates and in Early Human Trials" was presented by Dr. Jacques Genest.

Dr. Jacques Genest, MD, Director of the Division of Cardiology at McGill University Health Centre/Royal Victoria Hospital said, "We continue to be excited about the data that is being generated for RVX-208. It is important that our colleagues have access to this promising data which is why we have presented at this prominent conference. Resverlogix's novel drug demonstrated the ability to increase the production of ApoA-I and functional HDL. Notably we saw increases in prebeta-HDL particles, which improve HDL's ability to mediate cholesterol efflux."

"Today we presented interesting and consistent data from African Green monkey studies and our Phase 1a human clinical trial at the AHA," stated Dr. Jan Johansson, MD, Ph.D., Senior Vice President, Medical Affairs of Resverlogix. "The pharmacodynamic data from human healthy volunteers of which the majority had low HDL demonstrated that we have seen significant increases in ApoA-I production and HDL functionality, consistent with previous findings in the African Green monkey studies. Further investigation of the effect of RVX-208 on the HDL metabolic pathway is ongoing in humans and animals to establish the mechanisms of action and therapeutic potential in treating atherosclerotic cardiovascular disease."

During the presentation Dr. Genest reported that in an African Green monkey study treatment with RVX-208 resulted in a highly
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. RVX-208 Exploratory Study Illustrates Early Potential for Alzheimers Disease
2. International Steering Committee for RVX-208 IVUS Trial Formed
3. Phase 1b/2a Program Commences for RVX-208
4. Industry Leaders Select Resverlogixs RVX-208
5. Dosing for RVX-208 Phase 1a Clinical Study Completed
6. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
7. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
8. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
9. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
10. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
11. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 In recent years, the biopharmaceutical ... Big Data that can generate valuable insights. Despite this, ... Big Data have caused the biopharmaceutical sector to embrace ... According to a recent study by benchmarking ... a Big Data team or function in place; however, ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Market ... (Chem-Report ) signed a partnership agreement for quality ... authorised to distribute and sell research reports worked ... at Partners Department, commented upon the agreement: “Chem-Report ... on key petroleum and chemical markets on global ...
(Date:5/29/2015)... Research and Markets ( http://www.researchandmarkets.com/research/7bf7ff/cytogenetics ) ... report "Cytogenetics - Technologies, Markets and Companies" ... deals with cytogenetics in a broader sense rather ... chromosome structure and identify abnormalities related to disease. ... also referred to as molecular cytogenetics. The scope ...
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ... Companies"  to their offering.       ... a challenge in management. With nearly 8 ... seven major markets of the world and ...
Breaking Biology Technology:New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 3Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3
... New Opportunity to Serve Pharmaceutical Partner Interest for ... ... Transgenomic, Inc. (OTC,Bulletin Board: TBIO), a global genetic analysis ... laboratory services agreement,with the Guangzhou Family Planning Center in Guangzhou, ...
... NEWTON, Mass., March 31 Tryton Medical, Inc., ... treatment of,bifurcation lesions announced today that it has ... Two new investors, PTV Sciences and RiverVest Venture,Partners ... Rick Anderson,from PTV and Jay Schmelter from RiverVest ...
... 31 ExonHit Therapeutics, a drug,and diagnostic discovery company, ... join the Management Board on April 1st,2008. At the ... Board, until a new CEO is appointed., Philippe ... 2002,and has been a member of its Management Board ...
Cached Biology Technology:Transgenomic Opens Pharmacogenomics Laboratory in China 2Transgenomic Opens Pharmacogenomics Laboratory in China 3Tryton Medical, Inc. Closes $14 Million Financing 2Tryton Medical, Inc. Closes $14 Million Financing 3ExonHit Appoints a New Management Board 2ExonHit Appoints a New Management Board 3ExonHit Appoints a New Management Board 4
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
(Date:5/8/2015)... Calif. , May 8, 2015 Synaptics Inc. ... solutions, today announced that members of the executive management team ... Morgan 43rd Annual Technology, Media and Telecom Conference Date: ... Hotel in Boston, MA ... 27, 2015 Time: 2:45pm ET Location: The New York Palace ...
(Date:4/27/2015)... 27, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... customers the first week of May, 2015 and will ... May. Gino Pereira , Chief ... the company as Wocket® enters the consumer market. We ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... Biology of Reproduction includes a special paper by a ... mice results in shorter life expectancy and reduced body ... maternal age in women, such as abnormal numbers of ... potential negative effects on offspring from delayed motherhood have ...
... of Pennsylvania School of Medicine have developed an animal ... in humans. From this, they hope to develop new ... among the most lethal of cancers, with a one-year ... percent of patients, according to the National Cancer Institute. ...
... The World Health Organization (WHO) and the United Nations Children's ... halve deaths from measles, a leading vaccine-preventable killer, by the ... 39%, from 873 000 in 1999 to an estimated 530 ... the region with the highest burden of the disease, where ...
Cached Biology News:Disease progression model of pancreatic cancer developed by Penn researchers 2Disease progression model of pancreatic cancer developed by Penn researchers 3Measles Deaths Worldwide Drop By Nearly 40% Over Five Years 2
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
SAPK/JNK Antibody...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
Biology Products: